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Abstract: Vaccines are needed to protect from SARS-CoV-2, the virus causing COVID-19. Vaccines
that induce large quantities of high affinity virus-neutralizing antibodies may optimally prevent
infection and avoid unfavorable effects. Vaccination trials require precise clinical management,
complemented with detailed evaluation of safety and immune responses. Here, we review the pros
and cons of available vaccine platforms and options to accelerate vaccine development towards
the safe immunization of the world’s population against SARS-CoV-2. Favorable vaccines, used in
well-designed vaccination strategies, may be critical for limiting harm and promoting trust and a
long-term return to normal public life and economy.
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1. Introduction
The COVID-19 pandemic holds great challenges for which the world is only partially prepared [1].
SARS-CoV-2 combines serious pathogenicity with high infectivity. The latter is enhanced by the fact
that asymptomatic and pre-symptomatic individuals can transmit the virus, in contrast to SARS-CoV-1
and MERS-CoV, which were transmitted by symptomatic patients and could be contained more
efficiently [2,3]. To limit the damage of COVID-19, primary efforts focus on confinement, with physical
distancing and multiple further measures preventing infection [4,5]. At present, many investigations
aim at defining optimal strategies to limit viral transmission while simultaneously permitting business
and social activities [6]. Scientific insights and understanding of the biological mechanisms of the
virus and its capability to spread are primordial. Built on this knowledge, the practical strategies may
have at least three priorities: firstly, to continue hygiene measures and physical distancing; secondly, to
maximize the viral monitoring, both geographically and in time, to focus viral containment locally and
limit transmission wherever and whenever possible; thirdly, to rapidly increase the immunity of the
world’s population.
The diagnosis of SARS-CoV-2 infection is achieved through detection of viral RNA from a nasal
pharyngeal swab or saliva, by nucleic acid tests (NATs) or tests that detect viral protein antigens [5,7].
In infected individuals, the results are only positive for a relatively short time window, on average until
the 14th day after symptom onset [8]. Furthermore, a positive NAT result does not allow scientists
to conclude whether the affected person is or will become immune. Therefore, serological tests are
needed, as they can detect the various types of antibodies in the blood that persist for months or
even years.
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The world can probably not afford to let the majority of citizens undergo SARS-CoV-2 infection,
as the overall burden would be enormous. Current data indicate that a pandemic COVID-19 outbreak
infects only low percentages (usually in the single digit range) of the population, at least in countries
that take effective measures against viral spread [9]. To avoid pandemic propagation, the reproduction
number Ro (viral transmission) must remain below 1, meaning that each infected person transmits on
average to <1 additional individual, a key aim for continuously reducing case numbers. In contrast,
a reproduction number Ro of >1 means a highly unfavorable exponential increase of new infections.
Spontaneous disappearance of the virus is unlikely. Additional outbreaks are expected when the safety
measures are abandoned (Figure 1A). It may take significantly longer than one year until the majority
of the population acquire immunity through infection. As discussed further below, it will be important
to determine to which degree natural infection induces immunity and for how long it can protect
from re-infection.
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further below, it will be important to determine to which degree natural infection induces immunity 
and for how long it can protect from re-infection. 
The immune response to the SARS-CoV-2 involves innate immune activation and antigen-
specific responses of B and T cells [10]. Protection from viral infection is mainly achieved by virus-
neutralizing antibodies, a principle that applies to the vast majority of viral infections to which 
humans acquire robust immune protection due to infection or vaccination. It is urgent to develop 
vaccines aiming at the induction of protective immune responses, primarily through virus-
neutralizing antibodies specific for SARS-CoV-2. Although at least 1–2 years are required to make 
effective vac ines available globally, vaccination may s ill be the most ra id and ec nomical strategy 
to achieve widespread immune protection (Figure 1A). So-called “herd immunity” is reached when 
a critical percentage of the population has become immune, leaving the virus only limited local 
chances to circulate. This may be the case when >90% of persons are immune. However, broad 
immunization is already very helpful as soon as “only” approximately 60–70% have become immune, 
because relativ ly simple measures against viral spread will then be sufficient to cont in the virus. I  
case of future outbreaks of newly emerging microbes belonging to well-studied pathogen families, 
previously established experience will accelerate the development and use of vaccines, allowing us 
to reach herd immunity more rapidly (Figure 1B). Several organizations, including WHO, the 
Coalition for Epidemic Preparedness Innovations (CEPI) and the global Vaccine Alliance GAVI, are 
increasing preparation efforts for future pandemics. The lessons learned from SARS-CoV-2 will 
certainly support this development which, however, still remains very challenging [1]. 
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Figure 1. Model of immunity induced by infection and vaccination. (A) The world was poorly 
prepared for the first wave of SARS-CoV-2 spread (blue parts of the curve) [9]. Installed measures for 
limiting viral spread (*) largely halted further infections (black). Subsequent relaxing of these 
measures may lead to new waves of viral spreading. Even if this happens several times, it may take 
significantly more than one year until the majority of individuals become infected and immune. Once 
available, vaccination (green) will more rapidly induce immunity in a critical percentage of the 
population, which is necessary for herd immunity. The model scenarios shown are based on current 
evidence and the assumption that infection and proper vaccines induce immune responses that often 
protect from (re-) infection. However, there is increasing evidence that immunity to SARS-CoV-2 may 
only be temporary. This notion is not considered for this Figure because the quantitative importance 
of waning immunity remains still unknown. (B) In case of the emergence of a novel pathogen, 
vaccination may start much earlier provided one is prepared, i.e., has ample experience with this 
family of pathogens, enabling rapid vaccine development and production. Unfortunately, this was 
not the case for SARS-CoV-2. Not shown is the most favored scenario in which the population is 
previously vaccinated against a given pathogen, precluding viral spread, which is fortunately the case 
for immunity to many childhood diseases. Additionally, not shown is the in-between scenario in 
which a vaccine is available but larger parts of the population are not (yet) vaccinated, which can then 
be readily achieved. 
Here, we review the mechanistic understanding of immunity and vaccination against SARS-
CoV-2. We discuss vaccine target antigens and current vaccine candidates in preclinical and clinical 
testing. We also focus on the development and validation of precision serology to support preclinical 
and clinical evaluation of vaccine candidates and research on immune responses induced by natural 
infection. The basic and applied knowledge acquired during the last few decades is highly useful to 
design promising vaccines with increased likelihood of inducing protective immune responses and 
avoiding adverse effects and harmful disease enhancement. Now, probably more than ever, the 
world depends on rational effective strategies built on robust scientific evidence. 
2. Vaccine Development 
Vaccine development has started at a strongly accelerated pace already, shortly after the 
beginning of the SARS-CoV-2 outbreak [11–13]. At the time of finalizing this review, there are already 
more than twenty vaccines being tested in clinical trials. The WHO is publishing a regularly updated 
list of the vaccines in development [14]. As a specialist in the advance of epidemic vaccines, CEPI has 
organized a global consultation committee which helped to launch the COVID-19 Vaccine 
Development Taskforce, focusing on vaccine manufacturing and financing, in collaboration with 
GAVI and the World Bank [15]. Very useful comments on COVID-19 vaccines are regularly published 
in the scientific literature [16–19]. The knowledge gained through previous coronavirus outbreaks 
provides a favorable scientific basis for vaccine design (BOX 1)—for example, by helping to identify 
potentially protective epitopes, the Achilles heels of a virus. However, the fact that SARS-CoV-1 was 
spontaneously eliminated from the human population, and MERS-CoV was largely controlled 
Figure 1. Model of immunity induced by infectio and vaccinatio . (A) The world was poorly prepared
for the first wave of SARS-CoV-2 spread (blue parts of the curve) [9]. Installed measures for limiting
viral spread (*) largely halted further infections (black). Subsequent relaxing of these measures may
lead to new waves of viral spreading. Even if this happens several times, it may take significantly
more than one y ar until the majority of individuals be ome infected and immune. Once available,
vaccination (green) will more rapidly induce i munity in a critical percentage of the population, which
is necessary for herd immunity. The model scenarios shown are based on current evidence and the
assumption that infection and proper vaccines induce immune responses that often protect from (re-)
infection. However, there is increasing evidence that immunity to SARS-CoV-2 may only be temporary.
This notion is no considered for this Figure because the qu ntitative importance of wan ng immunity
remains still unknown. (B) In case of the emergence of a novel pathogen, vaccination may start much
earlier provided one is prepared, i.e., has ample experience with this family of pathogens, enabling
rapid vaccine development and production. Unfortunately, this was not the case for SARS-CoV-2. Not
shown is the most favored scenario in which the population is previously vaccinated against a given
pathogen, precluding viral spread, which is fortunately the case for immunity to many childhood
diseases. Additionally, not shown is the in-between scenario in which a vaccine is available but larger
parts of the population are not (yet) vaccinated, which can then be readily achieved.
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The immune response to the SARS-CoV-2 involves innate immune activation and antigen-specific
responses of B and T cells [10]. Protection from viral infection is mainly achieved by virus-neutralizing
antibodies, a principle that applies to the vast majority of viral infections to which humans acquire
robust immune protection due to infection or vaccination. It is urgent to develop vaccines aiming
at the induction of protective immune responses, primarily through virus-neutralizing antibodies
specific for SARS-CoV-2. Although at least 1–2 years are required to make effective vaccines available
globally, vaccination may still be the most rapid and economical strategy to achieve widespread
immune protection (Figure 1A). So-called “herd immunity” is reached when a critical percentage of
the population has become immune, leaving the virus only limited local chances to circulate. This may
be the case when >90% of persons are immune. However, broad immunization is already very helpful
as soon as “only” approximately 60–70% have become immune, because relatively simple measures
against viral spread will then be sufficient to contain the virus. In case of future outbreaks of newly
emerging microbes belonging to well-studied pathogen families, previously established experience
will accelerate the development and use of vaccines, allowing us to reach herd immunity more
rapidly (Figure 1B). Several organizations, including WHO, the Coalition for Epidemic Preparedness
Innovations (CEPI) and the global Vaccine Alliance GAVI, are increasing preparation efforts for future
pandemics. The lessons learned from SARS-CoV-2 will certainly support this development which,
however, still remains very challenging [1].
Here, we review the mechanistic understanding of immunity and vaccination against SARS-CoV-2.
We discuss vaccine target antigens and current vaccine candidates in preclinical and clinical testing. We
also focus on the development and validation of precision serology to support preclinical and clinical
evaluation of vaccine candidates and research on immune responses induced by natural infection.
The basic and applied knowledge acquired during the last few decades is highly useful to design
promising vaccines with increased likelihood of inducing protective immune responses and avoiding
adverse effects and harmful disease enhancement. Now, probably more than ever, the world depends
on rational effective strategies built on robust scientific evidence.
2. Vaccine Development
Vaccine development has started at a strongly accelerated pace already, shortly after the beginning
of the SARS-CoV-2 outbreak [11–13]. At the time of finalizing this review, there are already more than
twenty vaccines being tested in clinical trials. The WHO is publishing a regularly updated list of the
vaccines in development [14]. As a specialist in the advance of epidemic vaccines, CEPI has organized a
global consultation committee which helped to launch the COVID-19 Vaccine Development Taskforce,
focusing on vaccine manufacturing and financing, in collaboration with GAVI and the World Bank [15].
Very useful comments on COVID-19 vaccines are regularly published in the scientific literature [16–19].
The knowledge gained through previous coronavirus outbreaks provides a favorable scientific basis for
vaccine design (Box 1)—for example, by helping to identify potentially protective epitopes, the Achilles
heels of a virus. However, the fact that SARS-CoV-1 was spontaneously eliminated from the human
population, and MERS-CoV was largely controlled without the need for large-scale pharmaceutical
interventions, led to a drastic reduction in research funding during the last decade, severely limiting
further research and vaccine development. Therefore, there is currently only limited experience on
coronavirus vaccination; the first human coronavirus vaccine has yet to be approved.
In view of the urgency of making vaccines available for billions of people, one must primarily
focus on vaccines that can be produced in massive amounts and for which the production knowhow
and facilities are available or can be built rapidly [20].
Vaccines can be based on whole viruses (live-attenuated or inactivated), viral vectors, nanoparticles
or virus-like particles, subunit components, proteins/peptides, RNA, DNA or live cells. The first
vaccine trial against COVID-19 was started in China on February 15, 2020 (Table 1), using dendritic
cells that are genetically modified with structural and enzymatic proteins of SARS-CoV-2. A second
trial, also in China, was done with a similar vaccine, complemented by the infusion of antigen-specific
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T cells. While both of these vaccines are tested therapeutically in COVID-19 patients, most other
vaccines are tested in healthy volunteers. In the US, the first trial was launched in March 2020, using
lipid nanoparticle encapsulated mRNA encoding the spike (S) protein, sponsored by Moderna and the
National Institute of Health [21]. In early April 2020, a DNA vaccine trial was initiated with a plasmid
encoding the S protein, sponsored by Inovio Pharmaceuticals and CEPI. Since mid-April 2020, several
vaccines consisting of inactivated SARS-CoV-2 virus have been tested in China [22]. The first viral
vector COVID-19 vaccine was developed at the University of Oxford, UK. It is based on a chimpanzee
adenovirus and encodes the S protein [23], and it is now in phase 2/3 testing. A similar vaccine is based
on adenovirus-5. After promising results in phase 1 in Wuhan, China [24], this vaccine has also moved
forward, to a phase 2 trial (Table 1).
Table 1. SARS-CoV-2 vaccine candidates in clinical trials.
Vaccine Candidate Platform, Route ofAdministration
Target
(SARS-Cov-2) Developer
Trial Phase, Registry Number, Study Start,
Link
Synthetic minigene
transfected APCs
Covid-19/aAPC
Artificial antigen presenting
cells (APCs) modified with
lentiviral vector, s.c..
Selected conserved
structural and protease
protein domains
Shenzhen
Geno-immune Medical
Institute, China
Phase 1/2, NCT04299724, 15 February 2020
http://szgimi.org/en/news.php
Synthetic minigene
transfected APCs +
cytotoxic T cells
LV-SMENP-DC
Dendritic cells modified
with lentiviral vector, s.c.,
plus i.v. infusion of
cytotoxic T cells
Viral structural
proteins and a
polyprotein protease
Shenzhen
Geno-immune Medical
Institute, China
Phase 1/2, NCT04276896, 24 March 2020
http://szgimi.org/en/news.php
Recombinant adenovirus,
Ad5-nCoV
Viral vector, Adenovirus 5,
i.m. Spike protein
CanSino Biologics,
China
Phase 2, NCT04341389, 12 April 2020
http://www.cansinotech.com/homes/article/
plist/56.html
Recombinant adenovirus,
AZD1222
Viral vector
(non-replicating)
Chimpanzee Adenovirus,
i.m.
Spike protein University of Oxford,UK, & AstraZeneca
Phase 2b/3, 2020-001228-32, 4 May 2020
https://www.ox.ac.uk/news-and-events/
for-journalists
Recombinant adenovirus,
Gam-COVID-Vac (Lyo)
Viral vector, Adenoviruses
5 and 26, i.m. Spike protein
Gamaleya Research
Institute, Russia
Phase 1, NCT04436471, 17 June 2020
http://gamaleya.org/
Plasmid,
INO-4800
DNA, i.d., followed by
electroporation Spike protein
Inovio
Pharmaceuticals USA,
& CEPI
Phase 1, NCT04336410, 3 April 2020, and
Phase 2, https://www.inovio.com/our-focus-
serving-patients/covid-19/
Plasmid + adjuvant,
AG0301-COVID19 DNA, i.m. Spike protein
AnGes and Osaka
University, Japan
Phase 1/2, NCT04463472, 29 June 2020
https://www.anges.co.jp/en/
Plasmid,
GX-19 DNA, i.m. Spike protein Genexin Inc., Korea
Phase 1/2, NCT04445389, 17 June 2020
http://www.genexine.com/m62.php?cate=1
Lipid nanoparticle
encapsulated RNA,
mRNA 1273
mRNA, i.m. Spike protein
Moderna and Natl Inst
Allergy & Infectious
Diseases (NIAID), USA
Phase 2, NCT04405076, 25 May 2020
https:
//www.niaid.nih.gov/clinical-trials/safety-
immunogenicity-study-vaccine-covid-19
Lipid nanoparticle
encapsulated RNA,
BNT162
mRNA, i.m. Various viral ags (4vaccine candidates)
BioNTech, Germany, &
Pfizer, USA
Phase 1/2, NCT04368728, 29 April 2020
https://investors.biontech.de/press-releases
Lipid nanoparticle
encapsulated RNA.
CVnCoV
mRNA, i.m. Spike protein CureVac, Germany Phase 1, NCT04449276, 18 June 2020https://www.curevac.com/covid-19
COVAC1
(LNP-nCoVsaRNA)
mRNA in lipid
nanoparticle, i.m. Spike protein
Imperial College
London, UK
Phase 1, ISRCTN17072692, 1 April 2020
http://www.imperial.ac.uk/news
Protein + adjuvant,
NVX-CoV2373
Protein subunit vaccine,
i.m.
Spike protein and
Matrix-M adjuvant Novavax, USA
Phase 1/2, NCT04368988, 25 May 2020
http://ir.novavax.com/press-releases
Protein + adjuvant,
SCB-2019
Protein trimeric subunit
vaccine, i.m.
Spike protein, AS03,
CpG, alum adjuvant
Clover Biopharma,
Australia, GSK,
Dynavax
Phase 1, NCT04405908, 19 June 2020
http://www.cloverbiopharma.com/
SARS-CoV-2 inactivated
virus, PiCoVacc
Inactivated virus + alum
adjuvant Entire virus
Sinovac Research and
Development Co,
China
Phase 1/2, 16 April 2020, and Phase 3
http://www.sinovacbio.com/?optionid=
754&auto_id=904
SARS-CoV-2 inactivated
virus Inactivated virus Entire virus
Chinese Academy of
Medical Sciences
Phase 1/2, NCT04412538, 15 May 2020
http://english.cas.cn/newsroom/news/
SARS-CoV-2 inactivated
virus Inactivated virus Entire virus Sinopharm
Phase 1/2, ChiCTR2000031809, 11 April 2020
http://www.chinacdc.cn/en/
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Box 1. Vaccines against SARS-CoV-1 and MERS-CoV.
Currently there is no vaccine available against these two viral threats [25,26]. Nevertheless, several vaccine
candidates against SARS-CoV-1 have been developed based on VLPs, DNA, proteins and viruses (inactivated,
live-attenuated, recombinant vectors) [27,28]. While the majority were characterized preclinically, only a few were
tested in phase 1 clinical studies [29,30]. Against MERS-CoV, vaccines have been developed based on inactivated
virus, DNA and protein, generating preclinical data [31] and phase 1 trial results [32]. For both diseases, larger
studies to determine whether the vaccines could protect from natural infection have not been performed.
A study of non-human primates vaccinated with an inactivated virus showed high levels of
neutralizing antibodies, high levels of protection and no unfavorable disease enhancement [33].
In the past, some inactivated coronavirus vaccines have been shown to increase disease severity in
animals [34], as outlined below in the section on disease enhancement. Attention must be paid to the
high mutation rate (e.g., in the S1/S2 junction) which occurs in vitro during the production process
of inactivated viruses, requiring careful selection of appropriate vaccine strains. Attenuated viruses
may be promising, based on the long history of delivering successful vaccines [35,36] and novel
genetic techniques increasing the likelihood to create better vaccine strains [37]. Nevertheless, it takes
considerable time to identify strains with the right balance between sufficient attenuation and induction
of adequate immune responses. Furthermore, it will be highly demanding to produce sufficient
amounts of biosafety level-3 viruses to meet the high global needs. An attractive possibility may be to
use inactivated attenuated viruses, as the latter may be more easily grown than the wild-type virus.
Nanoparticles and virus-like particles (VLPs) have delivered successful vaccines. They can be
engineered to display epitopes of foreign viruses on their surface, rendering those epitopes highly
immunogenic. Molecules that stimulate innate immunity can be encapsulated within VLPs to enhance
immune responses and trigger favorable T helper type 1 (Th1) polarized immune responses (type 1
immunity) rather than potentially disease enhancing Th2 polarization [38].
The clinical trials that are now urgently needed to evaluate the COVID-19 vaccine candidates
serve to determine optimal vaccine dose and scheduling and whether multiple booster vaccinations
are required. Usually, more robust and long-term immunity can be induced by sequential vaccinations,
possibly necessary for those with expected weak immune responses, such as in elderly or immune
deficient individuals [39]. The clinical studies should also reveal whether the vaccine candidates induce
unwanted adverse effects such as local skin toxicity or fever and flu-like symptoms. Autoimmune
reactions may also occur, possibly with hematological or neurological manifestations [40]. Fortunately,
for most vaccines, severe unwanted adverse effects are very rare. Nevertheless, all safety issues must
be carefully studied before a vaccine is used widely.
Table 1. Anti-SARS-CoV-2 vaccines in clinical evaluation, registered at clinicaltrials.gov,
clinicaltrialsregister.eu and/or chictr.org.cn. At present, 24 and 142 vaccine candidates are in clinical
and preclinical evaluation, respectively [14].
The time required for vaccines reaching the wider public also highly depends on regulatory
authorities and their flexibility to accelerate the process and vaccine approval, as compared to standard
procedures established for less urgent health threats. The WHO roadmap [41] provides corresponding
guidelines and support for regulation and ethics and the use of platforms for developing vaccines and
therapeutics in the most efficient ways. Furthermore, properly designed clinical trials may greatly
reduce the time for clinical development—for example, by testing several vaccines simultaneously
in adaptive trials with a low number of shared control groups [11], requiring unusual cooperativity.
Ultimately, however, the most efficient and least toxic vaccines will succeed, even if their development
and production take longer. For more details on the production, distribution and safety/efficacy
assessment of the different vaccine platforms, we refer to the links in Table 1 and to the existing
literature [20,42–45].
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3. Vaccine Antigens
3.1. B Cell/Antibody Targets
Protection induced by currently available vaccines against viruses is primarily based on
virus-neutralizing antibodies. Such antibodies usually block the interaction of the virus with its
cellular receptor or prevent conformational changes required for fusion of the virus with the cell
membrane. The SARS-CoV-1 virus has been studied in substantial detail (Box 2). Recent investigations
have shown that the new SARS-CoV-2 virus uses a similar strategy for cell entry [46]. Attachment
to host cells takes place via binding of the viral S protein (Figure 2A) to the angiotensin-converting
enzyme 2 (ACE2), the viral receptor on host cells. Subsequently, the S protein is primed by host cell
proteases, by furin and the serine proteases TMPRSS2 and TMPRSS4, enabling the fusion of viral and
cellular membranes and the consequent entry of viral RNA into the host cell [47].
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Figure 2. SARS-CoV-2, the spike (S) protein and its receptor binding domain (RBD). (A) 
Coronaviruses have their name because they are decorated by prominent S proteins (yellow/green). 
It is the only viral protein that interacts with host cells and is the most diverging protein between 
different coronaviruses, particularly in its receptor binding domain (RBD, green). RBD binds to 
angiotensin converting enzyme 2 (ACE2, not shown) on the host’s cell surface. The fusion peptide 
(FP) fuses with the host cell membrane. Specific antibodies against RBD and FP can neutralize SARS-
CoV-2 NTD/CTD, N-/C-terminal domains. (B) RBD is glycosylated and methylated, which may 
hinder the induction of neutralizing antibodies. In contrast, the receptor interaction site (RIS, green) 
is not glycosylated. 
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to CD8 T cells. The one exception to this rule is in small fractions of dendritic cells that are capable of 
so-called cross-presentation, i.e., the cellular uptake of extracellular protein (especially particulate 
Figure 2. SARS-CoV-2, the spike (S) protein and its receptor binding domain (RBD). (A) Coronaviruses
have their me becaus t ey are decorat d b prominent S proteins (yellow/green). It is the o ly viral
protein that interacts with host cells and is the most diverging protein betw en different coronaviruses,
particularly in its receptor binding domain (RBD, green). RBD binds to angiotensin converting enzyme 2
(ACE2, not shown) on the host’s cell surface. The fusion peptide (FP) fuses with the host cell membrane.
Specific antibodies against RBD and FP can neutralize SARS-CoV-2 NTD/CTD, N-/C-terminal domains.
(B) RBD is glycosylated and methylated, which may hinder the induction of neutralizing antibodies.
In contrast, the receptor interaction site (RIS, green) is not glycosylated.
Box 2. The complexity of the SARS-CoV-1 family and antibody specificities.
The family of SARS-CoV-1 viruses consists of several groups of strains (comparable to many other viruses)
hosted by animals, humans or both [25]. The antibodies are specific for the spike (S), membrane (M), envelope
(E), nucleocapsid (N) and further viral proteins. Many of them are strain- or group-specific and thus recognize
only some but not all SARS-CoV-1 viruses. Antibodies may be neutralizing, although the majority are not. The
neutralizing antibodies are mainly specific for S protein [48–50] and, to a minor extent, also 3a protein [51].
Neutralizing antibody epitopes have been found to be highly conserved in several viral strains, indicating that
vaccines that elicit such antibodies are protective against multiple strains. These epitopes map primarily to the
receptor binding domain (RBD) of the S protein.
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S protein interaction with ACE2 is well described for both SARS-CoV-1 and -2 and relies on a
particular domain within the S protein, the so-called receptor binding domain (RBD). Indeed, most
antibodies capable of neutralizing coronaviruses are directed against RBD [50,52] (Box 2). Hence,
the primary immune mechanism of avoiding infection is through blocking viral attachment to ACE2.
Therefore, generating a vaccine inducing antibodies against RBD is the strategy used by the majority of
COVID-19 vaccine candidates [53]. It has recently been shown that RBD is glycosylated and methylated.
Generally, such posttranslational modifications are difficult to reproduce in vaccines, meaning that
vaccines may display (slightly) different epitopes than the virus. Consequently, the antibodies induced
by the vaccines may potentially be cross-reactive and non-protective. Interestingly, however, the
receptor interaction site (RIS) directly binding to ACE2 is not glycosylated, indicating that this RIS may
potentially be an ideal vaccine candidate [54,55] (Figure 2B).
The second most frequent choice is to use the whole S1 subunit. Other vaccine manufacturers use
the full-length S protein [32] and/or the fusion peptide (FP), which is part of the S2 unit and fuses with
the cell membrane and therefore also has neutralizing epitopes [56,57]. The latter is not the case for the
N-terminal domain (NTD) of the S protein and the membrane (M), envelope (E) and nucleocapsid (N)
proteins, all of which are not directly targeted by the current vaccine candidates [58], also because of
the risk of inducing disease enhancing antibodies.
Vaccine antigens may be used in the form of protein or peptides. A recent study has shown that a
SARS-CoV-2 S1-Fc fusion protein readily induced neutralizing antibodies in non-human primates [59].
Proteins and peptides may be rendered more immunogenic by formulating them with strong adjuvants.
Another strategy is to display vaccine antigens on VLPs, which are often highly immunogenic. Zha et
al. have shown that RBD-VLPs efficiently induced SARS-CoV-2-neutralizing antibodies in mice [60].
Further options are to insert RBD into viral vectors or DNA or RNA. A potential challenge is that the
induction of neutralizing antibodies depends on antigen display in the correct conformation, which is
not guaranteed when a protein or peptide is expressed and displayed in isolation at the site of injection.
This may be easier to achieve with the full S protein. However, S protein vaccination may induce
non-wanted antibodies in addition to the neutralizing ones directed against RBD [61]. Therefore,
provided that one succeeds in constructing a vaccine displaying RBD or even only the RIS in the proper
conformation, RBD or RIS may be preferable to the whole S protein.
The most obvious isotype to be induced by a COVID-19 vaccine is IgG, preferably the more
protective IgG1 and IgG3 subclasses. However, IgA may also be of importance to reduce infection of
mucosa and epithelial cells in the respiratory tract, as well as endothelial cells, which may be widely
targeted by the virus. While mucosal immunization at a large scale in a rapid fashion might be difficult,
the use of an adjuvant that triggers the production of IgA might be an important consideration. TLR7/8
and TLR9 ligands are good candidates as they potently promote IgA responses [62,63].
3.2. T Cell Targets
CD4 and CD8 T cells recognize and react to SARS-CoV-2 antigens [64], contributing to immune
protection, particularly by reducing disease severity [65,66]. To some extent, this may also be the case
for cross-reactive T cells induced by seasonal coronaviruses [67]. For disease prevention, T cells alone
are probably less potent than neutralizing antibodies [68]. Preventive anti-viral vaccines are successful
because they induce antibodies that neutralize viral particles in the extracellular space, immediately
after body entry and before viruses infect the host’s cells. Importantly, B cell responses and antibody
production are strongly promoted by CD4 T helper cells. Therefore, vaccines should simultaneously
induce both B cells and T cells.
T cell antigens must be presented by HLA molecules on the surface of antigen-presenting cells and
infected cells. As HLA molecules differ in most people due to the huge genetic HLA polymorphism,
viral recognition by T cells is based on a very large diversity of antigenic peptide/HLA complexes.
Each person has her/his own T cell specificities for those antigenic peptides that bind to her/his HLA
molecules. Vaccines containing short antigenic peptides or mini-genes will not work for most people,
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i.e., for those whose HLA molecules cannot present the respective antigenic peptides. In contrast,
vaccination with long peptides or full-length viral proteins or corresponding DNA/RNA are potentially
useful for many or all individuals.
CD8 cytotoxic T cells primarily recognize viral peptides that are synthesized within the infected
cell. In contrast, protein antigens that are picked up from the extracellular space are poorly presented
to CD8 T cells. The one exception to this rule is in small fractions of dendritic cells that are capable
of so-called cross-presentation, i.e., the cellular uptake of extracellular protein (especially particulate
antigens) and the presentation of processed peptides on HLA class I molecules to CD8 T cells [69].
Cross-presentation is rather slow and often rate limiting, which is a major reason why full-length
protein vaccines are inefficient for inducing CD8 T cell responses.
As compared to antibody induction, it is generally more challenging to induce long-term T
cell responses through vaccination. Most vaccines are either attenuated pathogens or more often
dead/synthetic vaccines which do not replicate in vivo. Yet, substantial microbial replication in vivo is
usually required for the induction of strong T cell responses [70]. It is therefore particularly difficult to
induce durable CD8 T cells by currently available vaccine technologies. For preventive vaccination,
this might not be a major problem, since CD8 T cells are not specialized to prevent infections. Rather,
CD8 T cells are important once host cells are infected. Therefore, these cells have their primary role in
individuals with established infection.
The induction of CD4 T cell help is often not rate limiting in vaccination, probably because
low numbers of these cells are already sufficient for supporting antibody production. Nevertheless,
vaccination may fail due to CD4 T cell non-responsiveness. Since T cell help can be provided by CD4
T cells with other specificities by intermolecular help, a smart approach is to supplement vaccines
by inserting microbial antigens to which most humans are already immunized [71]. The consequent
immune response will be stronger because boosting previously primed and established CD4 T cells is
more efficient than priming.
4. Disease Enhancement
4.1. T Cell-Dependent Disease Enhancement
It is not recommended to vaccinate for T cell responses without also efficiently inducing neutralizing
antibodies, because the latter are likely the crucial key effectors, and also because T cells, particularly
CD8 T cells, can cause extended tissue damage through their cytotoxicity against infected cells,
which is likely increased in the absence of antibodies that neutralize the viruses in the extracellular
space. Indeed, pure CD8 T cell responses induced by vaccination may enhance potentially lethal
immunopathology [72].
A concrete safety concern is the potential activation of Th2 cells. This was first observed in
a clinically tested respiratory syncytial virus (RSV) vaccine, which consisted of inactivated virus
and worsened clinical symptoms, with the deaths of two children upon infection with RSV. Disease
enhancement was caused by Th2 cell-mediated eosinophilia, a problem associated with vaccines
for respiratory vaccines. It is therefore essential to skew the response by vaccination towards Th1
polarization. Indeed, combining inactivated RSV with TLR-agonists reduces lung pathology upon
viral challenge in murine models [73]. Experience from SARS and MERS vaccine candidates indicates
that this risk exists also for coronavirus vaccines. Immunization with inactivated SARS-CoV-1 [34]
caused eosinophilic infiltration in murine models upon viral challenge. While immunization with
the viral nucleoprotein may be co-responsible [74], immunization with whole S protein and S
protein-based VLPs also triggered the induction of Th2 cells and eosinophilic inflammation upon viral
challenge [22]. In contrast, RBD based vaccines induced neutralizing antibodies in the absence of
disease enhancement [75]. It should be noted that it may also be advisable to avoid Th17 cells secreting
IL-17 upon stimulation, as this may lead to the pulmonary recruitment of neutrophils, contributing to
lung damage [76].
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4.2. Antibody-Dependent Disease Enhancement
Antibodies can either protect from infection and/or disease severity or be inefficient in doing so.
In addition, some antibodies can be harmful. Antibody-mediated enhanced disease may be caused by
two different mechanisms. The first is called antibody-dependent enhancement (ADE) of infection,
which occurs when antibodies promote viral uptake via Fcγ receptors (Figure 3A), thereby increasing
viral infection and pathogenicity [77,78]. ADE of infection is well known for flaviviruses, particularly
Dengue virus. The pathogenicity of these viruses occurs via their tropism to macrophages, which can
be enhanced by IgG antibodies enhancing viral uptake via Fcγ receptors, increasing cellular infection.
Particularly important are antibodies that are cross-reactive to different flavivirus family members.
Previous exposure to vaccines or infection-displaying antigens from a different Dengue virus serotype
may result in more severe Dengue fever, while infection with the same virus results in protection [79,80].
ADE of infection is preferentially mediated by low-affinity, cross-reactive antibodies and requires the
expression of Fcγ receptors by target cells, i.e., the cells that allow viral replication and thus give rise to
higher viral burden. Vaccines 2020, 8, x 11 of 21 
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There is no evidence in humans that ADE of infection occurs with SARS-CoV-1 [78]. However,
this has been demonstrated in feline infectious peritonitis [81]. Furthermore, the enhancement of
hepatitis was observed in ferrets challenged after vaccination with recombinant modified vaccinia
Ankara virus expressing the SARS-CoV-1 S protein [82]. Interestingly, similar to Dengue viruses, feline
coronavirus infects macrophages, making it more likely that disease severity may increase through
ADE-mediated viral uptake via Fcγ receptors. In contrast, human SARS coronaviruses appear to have
different tissue tropisms. SARS-CoV-1 infects pneumocytes in the lungs and surface enterocytes in the
small bowel [83], both of which do not express Fc receptors. Occasionally, SARS-CoV-1 was also found
in lung macrophages; localization was, however, restricted to phagosomes, suggesting that the virus is
degraded rather than infecting macrophages [84,85]. Since the two SARS viruses seem to have similar
cellular uptake mechanisms [46], COVID-19 is probably not worsened through ADE of infection.
The second mechanism is ADE of inflammation (Figure 3B). Activatory Fcγ receptors have special
signaling motifs (immunoreceptor tyrosine-based activation motifs; ITAMs) that may directly mediate
immune cell activation. Alternatively, Fcγ receptor-mediated viral uptake into immune cells may
promote the production of inflammatory molecules by triggering RNA sensors [86]. These pathways
lead to up-regulation of inflammatory cytokines and chemokines such as TNF, IL-6, CCL2 and CCL3
and reduced production of anti-inflammatory factors like IL-10 and TGFβ [74,86]. However, this
mechanism is unlikely to be induced by efficient vaccines, because it requires a high viral load, as
found in severely ill patients, a situation prevented by vaccine-induced neutralizing IgG antibodies.
Together, these data suggest that efficient and safe strategies of vaccination may be achieved
by the preferential usage of antigens that display neutralizing epitopes and the relative avoidance
of other epitopes to limit the risk through disease enhancing antibodies. Hence, RBD or RIS alone,
perhaps combined with the fusion peptide, could be optimal, as other parts of the S protein and the
other SARS-CoV-2 surface proteins could be potentially involved in ADE. Furthermore, vaccines that
promote Th1 cell responses are preferable, which can be achieved by using viruses/viral vectors or
innate immune stimulators with type 1 polarization capabilities [87–89].
5. Assays for Measuring Coronavirus-Specific Immune Responses
5.1. Serology
Most respiratory viruses induce IgM, followed by IgG and IgA antibody responses. Seroconversion
to SARS-CoV-2 infection occurred after 7 days in about half of the patients and by day 14 in nearly all
patients [90]. On average, the IgM response may peak 7 to 10 days after infection and the IgG response
at about 3 weeks [91]. Already, many serology assays are available for detecting SARS-CoV-2-specific
antibodies, some of which have reached sufficient reliability to be suitable for mass testing [7,92].
It is important to validate these assays such that results can be pooled and compared; centralized
laboratories may greatly contribute to this. Serological methods may be used to detect (prior) infection
or to evaluate possible protection from infection. Tests that indicate prior infection have to be highly
specific for SARA-CoV-2 and may include several viral proteins such as nucleoprotein and spike
protein to increase sensitivity. A test that discovers IgM antibodies may indicate ongoing infection,
while IgG in the absence of IgM may indicate clearance of the virus. IgA antibodies are potentially
useful if saliva is to be tested. The major issue of an IgA test is false negativity as IgA levels are often
low. Therefore, results may need to be verified by additional serological testing and/or NATs.
Unfortunately, most serology tests cannot directly determine whether the detected antibodies
neutralize the virus, a mandatory parameter if protection is to be predicted. Upscaling of neutralizing
antibody testing is limited because assays that directly demonstrate neutralization of SARS-CoV-2
must be done with the virus itself, which is only safe in highly specialized biosafety level-3 laboratories.
Many groups have developed neutralization assays with retroviruses or vesicular stomatitis virus (VSV)
pseudotyped with the SARS-CoV-2 S protein, allowing neutralization assays to be done in biosafety
level-2 facilities [78,93–96]. A surrogate for neutralization is antibodies specific for RBD, as most SARS
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virus-neutralizing antibodies are binding to RBD [52,96,97] (Figure 4A), although a small number of
antibodies may neutralize SARS without binding RBD [98] (Box 2). In contrast to tests indicating
infection, where false negative responses should be minimized, in assays predicting protection, false
positive results should be minimized. As RBD substantially differs between different coronaviruses
(binding to different receptors), this domain may also be ideal in terms of virus specificity.
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(A) Antibodies (orange or brown) specific for viral surface proteins can bind to SARS-CoV-2, in contrast
to antibodies (pink) specific for the viral nucleoprotein (N), which is not accessible in viable viruses.
Antibodies (orange) that bind to RBD are likely neutralizing, as they block the attachment of the virus
to its receptor (ACE2) on the surface of host cells (not shown). Most antibodies (brown) binding to
other moieties of the spike (S) protein (and antibodies binding to envelope or membrane proteins of
SARS-CoV-2; not shown) may not neutralize the virus. +, yes; +/- eventually; - no. (B) Virus-binding
antibodies may be induced by infection or vaccine candidates. Virus-like particles displaying RBD
(VLP-RBD) have a high likelihood of inducing neutralizing antibodies, provided that they display
RBD (green) in a repetitive and thus highly immunogenic manner. Alternatively, RBD-based vaccines
may be produced with RBD peptide, or viral vectors, DNA or RNA encoding RBD. The same vaccine
types may incorporate alternative antigens such as the full S protein (yellow), which may differ in
the degree of immunogenicity but may also be more likely to trigger virus-binding non-neutralizing
antibodies, possibly increasing the risk for antibody-dependent enhancement (ADE). Inactivated
and live-attenuated viruses (not shown) are expected to have relatively similar antigenic profiles to
wild-type virus. +++, strong; ++ intermediate; + weak.
SARS-CoV-2 is known to mutate, bearing the risk that existing neutralizing antibodies may lose
their protective power [78]. Even though this possibility cannot be excluded, coronaviruses appear to
change relatively slowly [64], in contrast to others such as influenza viruses or HIV-1. Coronaviruses
have an RNA proofreading capability [99], supporting the view that members of this virus family
depend on a relatively high degree of genetic stability. Indeed, common S protein mutations of
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SARS-CoV-2 are unlikely to affect antibody epitopes [50]. Thus, antibodies may keep their protective
power for a time period long enough to justify vaccine approaches. The major threat of coronavirus
evolution may not be the slow adaptation to existing immunity, as known from influenza as genetic
drift (requiring yearly new vaccines). Rather, the high danger comes from genetic recombination events
in animals infected with multiple viruses, as known from influenza as genetic shift, the typical origin
of influenza pandemics [100]. In any case, vaccine development must be accelerated to cope with
future challenges, since new coronaviruses or other microbes may threaten the world’s population.
5.2. Cytokine Measurements and T Cell Analysis
Assessment of Th2 cytokines such as IL-4/IL-5, or IL-17 as a marker for Th17 cells, may help to
evaluate the risk of disease enhancement. Furthermore, measurements of cytokines and inflammatory
parameters are important for monitoring patients with (risk of) severe SARS, in which strong cytokine
production and inflammatory reactions may be associated with lung damage [101,102]. Increased
levels of IL-6, ferritin, D-dimer, LDH and cardiac troponin I were found to be associated with increased
disease severity [103]. Since novel therapies must closely consider and target pathogenic mechanisms,
novel approaches are aiming at their early detection, hopefully permitting treatment early upon
infection so as to prevent progression to severe disease and a lethal outcome.
T cells are infrequently analyzed, and only in specialized laboratories, because viable cells require
special and labor intensive laboratory handling [104]. The great variability of peptide/HLA antigens
further complicates matters. In general, the presence of CD4 T helper cell responses can be deducted
by the demonstration of T cell help-dependent antibody responses which switch to IgG isoforms.
6. Immune Responses to Natural Infection Versus Vaccination
There is currently still only little understanding of the relationships between SARS-CoV-2 infection,
antibody responses and protection. A central issue is to determine whether vaccine candidates induce
immunity. There are serious ethical and technical limitations to challenging vaccinated volunteers with
live wild-type viruses with the aim of determining vaccine effectiveness. Alternatively, challenging
with seasonal coronaviruses or attenuated viruses could be considered for this purpose, substantially
reducing the risk for trial participants. In any case, trials should include volunteers with a high risk of
natural infection, such as populations in highly affected regions and healthcare workers.
Based on the current evidence, SARS-CoV-2 infection induces at least some degree of immunity,
perhaps even in the majority of individuals [105]. However, immunity might be less sound as compared
to immunity induced by SARS-CoV-1 infection, after which about 90% of patients had antibodies
still detectable after two years [106]. At three years post infection, IgG antibodies and neutralizing
antibodies were detectable in about 80% of patients [107]. SARS-CoV-2 induces milder disease, on
average, and is often only limited to the upper respiratory tract, in contrast to SARS-CoV-1, which
nearly always affected the lower respiratory tract as well. Re-infection with SARS-CoV-2 has been
reported but these cases could also reflect false negative results from viral RNA testing, potential
inadequate timing of sampling or reactivation of the virus [108,109]. For MERS, it is unknown whether
it induces protective immunity [110].
Interesting insights are offered from studying seasonal coronavirus common cold infections, which
occur typically in winter to spring and are usually of mild nature [111]. Indeed, the experimental
induction of relatively mild infection with seasonal coronaviruses were followed by short-lived
protection in the range of one year [112] or less [113]. More encouragingly, however, both studies
demonstrated that protection against experimental infection correlated with increased levels of IgA
and IgG antibodies present at the time of inoculation, both for homologous and heterologous viruses.
Furthermore, these seasonal coronavirus infections come in waves that may be self-limiting, as in
the years 1977–1979, when 90% of individuals had neutralizing antibodies against the 229E strain,
presumably reducing infection rates [112].
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A reason for the short duration of protection may be that coronaviruses have an interesting
strategy to evade neutralizing antibody induction. As discussed previously for adenoviruses [114],
SARS viruses may simply dilute the S protein in a sea of other proteins on the viral surface. In this
way, the spacing of S proteins becomes too large for optimal B cell activation, which is at a distance
of 5–10 nm [115], resulting in suboptimal generation of anti-S neutralizing antibodies. The fact that
this protein is long and embedded in the membrane of a large virus may reduce its highly repetitive
and rigid display, further reducing its immunogenicity. For these reasons, immune responses against
SARS viruses may be dominated by non-protective antibody responses. If these considerations apply,
SARS-CoV-2 may not be able to rapidly adapt to strong neutralizing antibody responses as it has
evolutionarily never been confronted with that challenge. Hence, COVID-19 vaccines designed to
optimally expose the RBD to the immune system for the efficient induction of neutralizing antibody
responses could potentially exert un unprecedented pressure on the virus, resulting in a halt of viral
spread (Figure 4B).
7. Conclusions and Perspectives
A major hurdle is the very limited pre-existing clinical experience with any coronavirus vaccine,
increasing the failure risk of COVID-19 vaccine trials and consequent delay. Fortunately, the ongoing
multitude of parallel vaccine development may compensate for the experience deficit. Furthermore,
there are many basic, translational and preclinical data in coronavirus research, which together with
the massive ongoing scientific effort forms a favorable basis for rapid progress.
We suggest that COVID-19 vaccines are promising when they induce large quantities of high
affinity neutralizing antibodies and only relatively low amounts of other antibodies and immune
responses bearing the risk of disease enhancement. Targeted by most neutralizing antibodies, RBD
may be the virus’ Achilles heel. However, it is still only partially possible to predict vaccine efficacy
and safety [116]. It remains justified to pursue the development of multiple different vaccine types,
also against other target antigens, possibly increasing the likelihood of success.
The large scale use of vaccines inducing neutralizing antibodies is the best option to maximize the
percentage of the population with immunity to SARS-CoV-2. It is realistic to achieve herd immunity
through vaccination, whereas broad natural infection appears too risky for humans and the economy,
unless viral spread induces immunity in much larger fractions of the world’s population than currently
known and expected, possibly in countries with less rigorous measures for avoiding viral spread. Due
to the urgency, COVID-19 vaccination is given high priority.
Once proven efficient and safe, vaccines should undergo registration to ensure that the world is
prepared for current and possible future SARS-CoV-2 outbreaks. At the same time, measures should
be put in place, as is the case for influenza virus vaccines, that allow the rapid adaptation of existing
vaccine platforms to newly emerging coronaviruses.
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